Last month, three of the largest insulin manufacturers announced they would take steps to reduce the price of their insulins. Eli Lilly and Company first announced it would reduce the list price for certain insulins by 70% and extend the $35 per month cap on out-of-pocket costs for people with Medicare that was enacted in...
We are only a few months into 2023, but the Endocrine Society has been busy advocating for its members. The Endocrine Society has traveled near (to Capitol Hill) and far (to Brussels and Bangkok) to advocate for our policy priorities. Our priorities include improved research, treatment, and prevention of diabetes; awareness of endocrine-related research, opportunities,...
The Endocrine Society advocates on behalf of our members, the patients they treat, and the science they research. This year, in addition to continuing our virtual advocacy, we had the opportunity to reintroduce several in-person advocacy activities. With help from our members, we successfully advocated for our policy priorities and raised awareness of the value...
Endocrine Society Weighs in on MPFS; Urges Congress to Avert Scheduled Medicare Cuts
Each year, the Center for Medicare and Medicaid Services (CMS) releases the Medicare Physician Fee Schedule (MPFS) rule, which outlines the agency’s payment and quality program policies for the upcoming year. Medicare policy often sets the bar for the private insurance market as well. Therefore, the payment policies and other revisions in the MPFS are...
Endocrine Society Urges Congress to Avert Proposed Medicare Physician Payment Cuts
On July 7, the Center for Medicare and Medicaid Services (CMS) released the annual Medicare Physician Fee Schedule (MPFS) proposed rule. This rule outlines the agency’s proposed payment and quality program policies for the upcoming year. This year’s rule proposes several important policy changes including allowing data collection on important telehealth services provided during the...
Endocrine Society Advances Key Priorities at AMA Annual Meeting
On June 10 – 15, the American Medical Association (AMA) House of Delegates met to establish policy positions on topics of importance to healthcare providers and patients. Endocrine Society delegates Amanda Bell, MD, and Palak Choksi, MD, successfully advocated for several of our key policy priorities, including insulin affordability, obesity, women’s health, climate change, and...
Endocrine Society Advises EU Policymakers on Chemicals Strategy
As part of our global advocacy for science-based policies to reduce exposure to harmful endocrine-disrupting chemicals (EDCs), the Endocrine Society has a seat on an advisory body to the European Commission on the implementation of the Chemicals Strategy for Sustainability (CSS). On May 18, members of the advisory met in Brussels, Belgium, to adopt a...
Learn more about our advocacy and how you can get involved Today’s political environment is partisan, turbulent, and hard to navigate. Despite this challenge, the Endocrine Society works with the U.S. Congress, the White House, federal agencies, and global policymakers to influence the legislative and regulatory policies affecting endocrine-related research and practice. We advocate for...
